Sun. Dec 3rd, 2023
Vector Space Biosciences, Oracle, and NVIDIA Collaborate on New CubeSat Launch Platform

Vector Space Biosciences, Inc., in collaboration with Oracle and NVIDIA, has introduced a new small satellite (CubeSat) launch platform for biotechnology and pharmaceutical companies. This platform is powered by a biosciences lab, a CubeSat lab, and a language modeling/AI lab. It includes highly targeted biological language modeling, generative AI, protein sequence matching, vector databases, and advanced visualizations.

The goal of this platform is to develop countermeasures against diseases associated with the stressors resulting from human spaceflight. These countermeasures not only protect humans in space but also serve as new forms of precision medicine for all mankind.

Once a CubeSat is designed, developed, and launched, data is transmitted to ground stations in collaboration with Microsoft Azure Space. This data, along with current biomedical data, is preprocessed for language modeling. Real-time hidden relationship networks are constructed between genes, proteins, diseases, drug compounds, and other biochemicals using feature vectors extracted from trained models.

The data generated from CubeSats in space is of high-value and enables new discoveries in drug discovery, development, design, and drug repurposing. An example of the latter is Novo Nordisk’s weight loss drug, Wegovy (semaglutide), which has been shown to help patients lose an average of 15% of their weight and reduce the incidence of heart attack, stroke, or death from heart disease by 20%.

Vector Space Biosciences founder and CEO, Kasian Franks, emphasizes the importance of understanding how to protect and repair the human body during spaceflight in order to establish lunar bases or go to Mars. By focusing on solutions in this area, new therapeutic applications in precision medicine can be developed and repurposed for the benefit of all mankind.

Vector Space Biosciences, trading under the cryptocurrency symbol SBIO, facilitates payments through its subsidiary, Vectorspace AI, and its utility token, VXV.

Vector Space Biosciences, Inc., designs, develops, and launches biological small satellites (CubeSats) to generate and interpret unique datasets related to microgravity and radiation. Their collaboration with scientific collaborators aims to develop countermeasures against diseases associated with stressors connected to protecting and repairing the human body during spaceflight. The company’s platform uses scientific data engineering pipelines to build targeted language models that power operations in space biosciences, biotechnology, and pharmaceutical development. By working with leading scientific labs, Vector Space Biosciences aims to accelerate new hypothesis generation and discoveries in space biosciences, including nanotechnology and nanomedicines. Their advanced language modeling/AI technologies can produce over 100 billion different real-time datasets to accelerate discoveries. These innovations in space biosciences have implications for all industries, including the financial markets, and contribute to the development of precision medicine for all humanity.

For more information, please visit